Spread the love

Idea Proposed/Formulated byDr L Boominathan Ph.D.

Web: http://genomediscovery.org

Terms & Conditions applhttp://genomediscovery.org/registration/terms-and-conditions/

To citeBoominathan, Molecular therapy for Metabolic disorders: C/EBPβ increases insulin sensitivity, restores mucosal immunity and decreases endotoxaemia via up regulation of Interleukin-22 (IL-22), 15/October/2014, 7.51 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite drop us a line at info@genomediscovery.org

* Research cooperation

Significance: This study suggests, for the first time, that C/EBPβ, by increasing the expression of IL-22, it may increase insulin sensitivity, restore gut immunity and decrease endotoxaemiaTogether, this study suggests that pharmacological formulations encompassing C/EBPβ activators” may be used to treat metabolic disorders, including T2DM and cardiac diseases.

Spread the love